1. Home
  2. CRSP vs PIPR Comparison

CRSP vs PIPR Comparison

Compare CRSP & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$61.85

Market Cap

5.0B

Sector

Health Care

ML Signal

N/A

Logo Piper Sandler Companies

PIPR

Piper Sandler Companies

N/A

Current Price

$74.57

Market Cap

4.9B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
PIPR
Founded
2013
1895
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.9B
IPO Year
2016
2003

Fundamental Metrics

Financial Performance
Metric
CRSP
PIPR
Price
$61.85
$74.57
Analyst Decision
Buy
Buy
Analyst Count
17
3
Target Price
$70.29
$91.38
AVG Volume (30 Days)
1.5M
503.5K
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
2.26%
EPS Growth
N/A
54.49
EPS
N/A
1.87
Revenue
$289,590,000.00
$1,904,217,000.00
Revenue This Year
$807.72
$12.30
Revenue Next Year
$172.52
$13.55
P/E Ratio
N/A
$38.96
Revenue Growth
9169.85
24.33
52 Week Low
$44.12
$69.16
52 Week High
$78.48
$380.26

Technical Indicators

Market Signals
Indicator
CRSP
PIPR
Relative Strength Index (RSI) 66.87 43.70
Support Level $50.17 $73.59
Resistance Level $60.10 $78.53
Average True Range (ATR) 2.13 1.99
MACD 0.89 -0.20
Stochastic Oscillator 88.40 20.74

Price Performance

Historical Comparison
CRSP
PIPR

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.

Share on Social Networks: